Mitoxantrone hydrochloride liposome

also known as Lipo-MIT · Liposomal mitoxantrone · PLM60

Developed for: acute myeloid leukemia · diffuse large B-cell lymphoma · breast cancer · cancer · childhood acute myeloid leukemia · mature T-cell and NK-cell non-Hodgkin lymphoma · nasopharyngeal carcinoma · peripheral T-cell lymphoma, not otherwise specified
Investigated by: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · The First Affiliated Hospital of Soochow University · The First Affiliated Hospital with Nanjing Medical University · CSPC Ouyi Pharmaceutical Co., Ltd. · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
+6 more
· Children's Hospital of Soochow University · Conjupro Biotherapeutics, Inc. · First Affiliated Hospital Xi'an Jiaotong University · First Affiliated Hospital of Zhejiang University · Institute of Hematology & Blood Diseases Hospital, China · Ming-Yuan Chen

Trials 12 · a red edge is where a trial was stopped

today NCT07486479 · Ph 3 NCT07070479 · Ph 2 NCT06953739 · Ph 3 NCT06385808 · not/applicable NCT06447090 · Ph 2 NCT06434662 · Ph 2 NCT06221683 · Ph 2 NCT06156761 · not/applicable NCT05784987 · not/applicable NCT05823701 · Ph 2 NCT05089461 · Ph 2 NCT03553914 · Ph 1/2

202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/21 trial
Phase 1/2	NCT03553914	Jan 2021 → Jan 2024	peripheral T-cell lymphoma, not otherwise specified	Conjupro Biotherapeutics, Inc.	Withdrawn	No outcome recorded
Phase 26 trials
Phase 2	NCT07070479	Jun 2025 → Jan 2027 expected	nasopharyngeal carcinoma	Ming-Yuan Chen	Recruiting	No outcome recorded
Phase 2	NCT06447090	Apr 2024 → May 2027 expected	acute myeloid leukemia	Institute of Hematology & Blood Diseases Hospital, China	Recruiting	No outcome recorded
Phase 2	NCT06434662	Feb 2024 → Jun 2025	acute myeloid leukemia	First Affiliated Hospital of Zhejiang University	Unknown	No outcome recorded
Phase 2	NCT06221683	Jan 2024 → Dec 2028 expected	childhood acute myeloid leukemia	Children's Hospital of Soochow University	Recruiting	No outcome recorded
Phase 2	NCT05823701	Sep 2022 → Dec 2023	diffuse large B-cell lymphoma	The First Affiliated Hospital of Soochow University	Unknown	No outcome recorded
Phase 2	NCT05089461	Mar → Jun 2022	cancer	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Suspended	No outcome recorded
Phase 32 trials
Phase 3	NCT07486479	Mar → Dec 2026 expected	acute myeloid leukemia	The First Affiliated Hospital of Soochow University	Not yet recruiting	No outcome recorded
Phase 3	NCT06953739	May 2025 → Dec 2027 expected	mature T-cell and NK-cell non-Hodgkin lymphoma	The First Affiliated Hospital with Nanjing Medical University	Not yet recruiting	No outcome recorded
Phase not applicable3 trials
—	NCT06385808	May 2024 → Dec 2026 expected	acute myeloid leukemia	First Affiliated Hospital Xi'an Jiaotong University	Not yet recruiting	No outcome recorded
—	NCT06156761	Nov 2023 → Apr 2024	breast cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Unknown	No outcome recorded
—	NCT05784987	Apr 2023 → Jan 2024	diffuse large B-cell lymphoma	The First Affiliated Hospital with Nanjing Medical University	Unknown	No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

Field	Value	Cited text
Known as	Mitoxantrone Hydrochloride Liposome	“Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (12 mg/m2) on day 1, every 3 weeks” NCT06953739 ↗ 9 “Mitoxantrone Hydrochloride Liposome” NCT06385808 ↗ NCT07070479 ↗ NCT05089461 ↗ NCT06434662 ↗ NCT06156761 ↗ NCT06221683 ↗ NCT06447090 ↗ NCT07486479 ↗ NCT05784987 ↗
Known as	Lipo-MIT	“Mitoxantrone Hydrochloride Liposome (Lipo-MIT), a nanoparticle formulation with a 60-nm particle size, is designed to reduce toxicity and enhance tumor targeting.” PMID 42050512 ↗ Apr 2026 1 “mitoxantrone hydrochloride liposome (Lipo-MIT)-based rituximab” PMID 42426809 ↗ Jul 2026
Known as	Liposomal mitoxantrone	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05823701 ↗
Known as	PLM60	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03553914 ↗
Route	Intravenous	“administered via intravenous infusion” NCT03553914 ↗